Clay Siegall undoubtedly remains one of the current key contributors to the health sector. Founder and CEO of Seattle Genetics, Dr. Siegall has launched significant biotech developments that have brought huge benefits when it comes to cancer healthcare. In one of his recent interviews published by inspirery.com, Clay Siegall shared his entrepreneurial experience with both young and established entrepreneurs.
Asked about his inspiration and how he got into biotech business, Siegall explained that he always had passion for medicine, technology and a drive to innovate alternative healthcare approaches. He specifically got interested in cancer treatment first following a medication experience by a family member. Clay Siegall points out that his initiative was not fully focused on profit generation but to help patients as well as help him be his own boss. The Dr. shared with readers that Seattle Genetics generates revenue through various avenues including sell of drugs, production partnerships, and licensing of the company’s technologies and processes.
Clay Siegall was happy to note that Seattle Genetics’ FDA approved antibody drug conjugate was the first ADC to be approved by FDA. He shares with other entrepreneurs that his company actually became profitable about 10 years after IPO. Like several other successful business leaders, Clay admitted that at some point in business he wasn’t sure on what the future had for Seattle Genetics. His team embraces a unique marketing strategy that involve wine and dinning as well as meetings to negotiate deals and generate new business. Dr. Clay believes that hard work and total commitment has greatly contributed towards his success.
Dr. Clay Siegall
Clay Siegall pursued a B.S in Zoology from the University of Maryland before earning a PhD in Genetics from the famous George Washington University. Before launching Seattle Genetics, Siegall worked with a number of organizations serving in various capacities. He worked with Bristol-Myers Squibb Pharmaceutical Research Institute, National Institute of Health, and National Cancer Institute among several other organizations.
Dr. Siegall established Seattle Genetics in 1998 and has since put it in the global map specializing in targeted therapy. Under his innovative leadership, the company has developed a significant number of products and processes including over 20 drugs. Through its strategic collaborations with Genentech, Bayer, and Pfizer, Seattle Genetics has made tremendous achievements and Siegall believes the future is bright for his business.